Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Cannara reported Q2/26 revenue of $27.2M (+2% YoY), missing our estimates due to seasonal provincial purchasing trends which should reverse over the coming quarters, resuming higher levels of growth.</li>
<li>Gross margin of 43% exceeded expectations and remained above management’s targets, highlighting continued operational efficiency.</li>
<li>Market share continued to expand nationally and in Quebec, reinforcing Cannara’s relative strength despite declining industry sales.</li>
</ul>


Cannara reported Q2/26 revenue of $27.2M (+2% YoY), missing our estimates due to seasonal provincial purchasing trends which should reverse over the coming quarters, resuming higher levels of growth.
Gross margin of 43% exceeded expectations and remained above management’s targets, highlighting continued operational efficiency.
Market share continued to expand nationally and in Quebec, reinforcing Cannara’s relative strength despite declining industry sales.


LOVE: 부진한 분기 실적에도 불구하고 업계 평균을 상회하는 성과

Cannara Biotech

LOVE: 부진한 분기 실적에도 불구하고 업계 평균을 상회하는 성과